MEI Pharma (MEIP)
(Delayed Data from NSDQ)
$3.10 USD
-0.16 (-4.91%)
Updated Apr 25, 2024 03:56 PM ET
3-Hold of 5 3
A Value F Growth C Momentum C VGM
Income Statements
Fiscal Year end for MEI Pharma, Inc falls in the month of June .
All items in Millions except EPS data.
6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 | 6/30/19 | |
---|---|---|---|---|---|
Sales | 49 | 41 | 26 | 29 | 5 |
Cost Of Goods | 0 | 0 | 1 | 3 | 4 |
Gross Profit | 49 | 41 | 24 | 26 | 1 |
Selling & Adminstrative & Depr. & Amort Expenses | 86 | 116 | 94 | 51 | 47 |
Income After Depreciation & Amortization | -37 | -75 | -70 | -25 | -46 |
Non-Operating Income | 5 | 21 | 19 | -21 | 29 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -32 | -54 | -51 | -46 | -17 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -32 | -54 | -51 | -46 | -17 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -32 | -54 | -51 | -46 | -17 |
Depreciation Footnote | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 | 6/30/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -36 | -75 | -69 | -24 | -46 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -37 | -75 | -70 | -25 | -46 |
Earnings Per Share Data | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 | 6/30/19 |
---|---|---|---|---|---|
Average Shares | 6.66 | 6.26 | 5.72 | 4.55 | 3.62 |
Diluted EPS Before Non-Recurring Items | -5.02 | -13.40 | -16.80 | -5.20 | -12.40 |
Diluted Net EPS (GAAP) | -4.78 | -10.00 | -13.60 | -10.20 | -15.00 |
Fiscal Year end for MEI Pharma, Inc falls in the month of June .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 65.30 | 1.46 | 5.89 |
Cost Of Goods | NA | 3.91 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | -3.91 | 65.30 | 1.46 | 5.89 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 8.02 | 10.02 | 12.54 | 22.28 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -11.93 | 55.28 | -11.08 | -16.39 |
Non-Operating Income | NA | 0.87 | 1.09 | 1.05 | 0.95 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -11.06 | 56.37 | -10.03 | -15.44 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -11.06 | 56.37 | -10.03 | -15.44 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -11.06 | 56.37 | -10.03 | -15.44 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 6.66 | 6.66 | 6.66 | 6.66 |
Diluted EPS Before Non-Recurring Items | NA | -1.66 | 8.46 | -1.51 | -2.32 |
Diluted Net EPS (GAAP) | NA | -1.66 | 8.46 | -1.66 | -2.32 |